Trial Sites for Pellepharm Phase III Patidegib Topical Gel 2%

Trial Sites for Pellepharm Phase III Patidegib Topical Gel 2%

Thank you for your interest in participating in the Phase III Patidegib 2% topical gel clinical trial for the reduction of disease burden of basal cell carcinomas in Gorlin Syndrome sponsored by PellePharm. The participating sites in the US are listed below and is divided into three categories based upon their current status of enrollment.

Tier 1: Sites that are fully activated and can actively screen on-site and dose patients.
Tier 2: Sites that can pre-screen and where activation in eminent.
Tier 3: Sites that have committed to participating in the trial but have not completed activation yet.

Please note:  If there is no site close to you or a site has not opened yet, but you are interested in participating now, PellePharm is reimbursing patients for travel to remote sites. However, you must be willing to commit to a monthly trip to that site for one year and you cannot switch to another site mid-study.  As site status changes, this list will be updated accordingly, so please stay in touch with our office. If all goes as planned, all sites should move up to the tier 1 status within the next few months.

Tier 1 – Sites that are fully activated and can actively screen on-site and dose patients.
State Site Location Site Investigator Study Coordinator Study Coordinator Contact Info
CT New Haven (Yale) Dr. Sean Christensen Mahin Dawood 203.785.5505 or mahin.dawood@yale.edu
FL Ormond Beach Dr. James Solomon Sandra Warrington 386.523.0768 or Sandra.warrington@ameridermresearch.com
IN Indianapolis Dr. William Hanke Jami Zenor 317.660.4862 or jzenor@thelassi.com
MN Minneapolis (Univ. of Minnesota) Dr. Ian Maher Irmina Wallander 612.624.5721 or wall0396@umn.edu
CA Redwood City (Stanford Univ.) Dr. Anne Chang Alexander Valencia 650.498.5185 or alxnder@stanford.edu
CA San Francisco Dr. Sarah Arron Christine Aroyan 415.353.9684 or

christine.aroyan@ucsf.edu

MO St. Louis (St. Louis Univ Hosp) Dr. Patricia Missall Rosemary King 314.256.3436 or rosemary.king@health.slu.edu
OR Portland Dr. Anna Bar Christina Armstrong 503.494.4770 or

armstrch@ohsu.edu

NC Durham Dr. Meenal Kheterpal Kim Scoggins 919-684-1830 or Kim.scoggins@duke.edu

 

Tier 2 – Sites that can pre-screen and where activation in eminent.
State Site Location
FL Miami
NY New York
NY New York
PA Philadelphia
Tier 3: Sites committed to participating in the trial but have not completed activation yet.
AZ Phoenix
CA Newport Beach
IL Chicago
MI Ann Arbor
OH Cleveland
PA Hershey
TX Houston
UT Salt Lake City
Canada British Columbia
Canada Toronto

 

You can also learn more about this clinical trial by visiting  www.gorlinstudy.com.